Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

被引:5
|
作者
Ji, Ying [1 ]
Wang, Yan-Li [2 ]
Xu, Fang [1 ]
Jia, Xi-Bei [1 ]
Mu, Su-Hong [1 ]
Lyu, Hui-Yan [1 ]
Yuan, Xue-Ying [1 ]
Na, Shi-Ping [1 ]
Bao, Yu-Shi [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Nephrol, 23 Youzheng St, Harbin 150001, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Rheumatol, Harbin, Peoples R China
关键词
podoplanin; C-type lectin-like receptor 2; nephrotic syndrome; hypercoagulable state; thrombosis; VENOUS THROMBOSIS; TUMOR-METASTASIS; RECEPTOR CLEC-2; THROMBOEMBOLISM; PLATELETS; INTEGRITY; ROLES; MICE;
D O I
10.1177/10760296221108967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = -0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] IDIOPATHIC NEPHROTIC SYNDROME IS NOT ASSOCIATED WITH ELEVATED SWEAT CHLORIDE CONCENTRATION
    Guglani, L.
    Jain, A.
    Abdulhamid, I
    PEDIATRIC PULMONOLOGY, 2014, 49 : 380 - 381
  • [42] THE SOLUBLE IMMUNE-RESPONSE SUPPRESSOR PATHWAY IN NEPHROTIC SYNDROME
    SCHNAPER, HW
    SEMINARS IN NEPHROLOGY, 1989, 9 (01) : 107 - 111
  • [43] Erythrocytes and Platelets May Contribute to Hypercoagulability In Nephrotic Syndrome Through Enhanced Phosphatidylserine Exposure and Microparticles Release
    Gao, Chunyan
    Xie, Rui
    Wang, Jing
    Yu, Chengyuan
    Tan, Xiaoyan
    Li, Jianan
    Xie, Rujuan
    Zhou, Jin
    Gilbert, Gary E.
    Shi, Jialan
    BLOOD, 2011, 118 (21) : 20 - 20
  • [44] Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome
    Matsumoto, K
    Kanmatsuse, K
    CLINICAL NEPHROLOGY, 2001, 55 (04) : 269 - 274
  • [45] Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome
    Butthep, Punnee
    Chunhakan, Sirichan
    Tangnararatchakit, Kanchana
    Yoksan, Sutee
    Pattanapanyasat, Kovit
    Chuansumrit, Ampaiwan
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (10) : 894 - 897
  • [46] The Detection of Plasma Soluble Podoplanin of Patients with Breast Cancer and Its Clinical Signification
    Zhu, Xinyi
    Xu, Mengqiao
    Zhao, Xingpeng
    Shen, Fei
    Ruan, Changgeng
    Zhao, Yiming
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 13207 - 13214
  • [47] Elevated levels of soluble CD40 ligand in patients with Sjogren's syndrome
    Ohashi, H
    Karahshi, T
    Kondoh, S
    Hayashi, H
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 112 - 112
  • [48] Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome
    Beanlands, Heather
    Maione, Maria
    Poulton, Caroline
    Herreshoff, Emily
    Hladunewich, Michelle A.
    Hailperin, Marilyn
    Modes, Mary Margaret
    An, Lawrence
    Nunes, Julie Wright
    Trachtman, Howard
    Nachman, Patrick
    Gipson, Debbie S.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 98 - 105
  • [49] Hyporeninemic hypoaldosteronism in patients with nephrotic syndrome
    Usberti, M
    Gazzotti, RM
    AMERICAN JOURNAL OF NEPHROLOGY, 1998, 18 (03) : 251 - 255
  • [50] CEREBRAL INFARCTION IN PATIENTS WITH NEPHROTIC SYNDROME
    MARSH, EE
    BILLER, J
    ADAMS, HP
    KAPLAN, JM
    STROKE, 1991, 22 (01) : 90 - 93